Improving the immune response to bacterial sepsis
Targeting the host immune response during sepsis
This study is looking at ways to boost the immune system's ability to fight off serious bacterial infections like sepsis, by focusing on how certain immune cells can be made stronger, which could help patients recover better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10662372 on NIH RePORTER |
What this research studies
This research investigates how to enhance the body's immune response to bacterial infections, specifically sepsis, which is a severe and often fatal condition. It focuses on understanding the interactions between the immune system and bacteria, particularly how certain immune cells, like macrophages, can be improved to better fight off infections. By studying the role of a protein called p120 catenin in these immune cells, the research aims to develop new strategies that could help patients clear bacterial infections more effectively. The approach includes both laboratory studies and potential applications in clinical settings to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bacterial sepsis who are experiencing severe immune response issues.
Not a fit: Patients with sepsis caused by non-bacterial pathogens or those who are not critically ill may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce mortality rates from bacterial sepsis.
How similar studies have performed: Previous research in cancer immunotherapy has shown success with similar approaches to enhancing immune responses, suggesting potential for this strategy in infectious diseases.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Hu, Guochang — University of Illinois at Chicago
- Study coordinator: Hu, Guochang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.